Topical Diclofenac sodium 2 percent gel vs Tretinoin 0.05 percent cream for the treatment of dark raised skin lesions over the face -A Randomised controlled trial .

Topical Diclofenac sodium 2 percent gel vs Tretinoin 0.05 percent cream for the treatment of Seborrheic keratosis -A Randomised controlled trial .

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/073000

Enrollment

Registered

2024-08-27

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: L82- Seborrheic keratosis

Interventions

Intervention1: Topical Diclofenac sodium 2% gel: 2 percent twice daily application over the seborrheic keratosis for 3 months Control Intervention1: Tretinoin 0.05% cream: 0.05 percent twice daily app

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adult patients with seborrheic keratosis 2.Not used any topical agents for treatment of Seborrheic Keratosis for past 6 months.

Exclusion criteria

Exclusion criteria: 1.Patients having Seborrheic Keratosis located in intertriginous sites and near eyelids. 2.Patients having DPN’s and stucco keratosis.

Design outcomes

Primary

Measure	Time frame
Clearance rate will be assessed by measuring reduction in size of Seborrheic KeratosisTimepoint: Follow up will be done every 2 weeks for 3 months.	—

Secondary

Measure	Time frame
1.To document the adverse effects of Diclofenac sodium 2% gel and Tretinoin 0.05% cream in the treatment of Seborrheic Keratosis. 2.To compare dermoscopic changes of Seborrheic Keratosis after treatment. Timepoint: Follow up will be done every 2 weeks for 3 months.	—

Countries

India

Contacts

Public ContactVAISHNAVI

Aarupadai veedu medical college and hospital

damayandhi.kaliaperumal@avmc.edu.in9488511884

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026